HLA-C and neoplasm: iNKT cells own several favorable characteristics that encourage their clinical applications, including [1] potent anti-tumor function through direct cytotoxicity or αβT cell cross-priming [137], [2] natural ability to effectively traffic to the tumor site [138], [3] disrupting the suppressive activity of TAMs and myeloid-derived suppressor cells (MDSCs) in CD1d-dependant manner, [4] recognition and cytotoxic killing of TAMs independently of CD1d via NKRs [106], [5] and no risk of GvHD due to lack of MHC engagement [139, 140].